Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

multiple myeloma

- PMLiVE

FDA grants orphan drug status to Allogene’s BCMA-targeted treatment for multiple myeloma

The decision follows the RMAT designation granted by the FDA in April

- PMLiVE

Sanofi signs $1bn licence agreement for Eureka’s novel multiple myeloma drug

Multiple myeloma is the second most common blood cancer

- PMLiVE

J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma

Darzalex treatment regimen reduced risk of death by 32% after nearly five years follow-up

- PMLiVE

FDA priority review granted for J&J, Legend Biotech’s myeloma CAR T therapy

CAR T therapy demonstrated an overall response rate of 97% in relapsed/refractory multiple myeloma patients after 12.4 months

- PMLiVE

Pfizer pauses enrolment for trial evaluating anti-BCMA bispecific antibody

Trial pause follows reports of three cases of peripheral neuropathy in phase 1 study

- PMLiVE

Second Sarclisa combination regimen for multiple myeloma approved in EU

Second indication for Sarclisa covers drug’s use in combination with another standard myeloma treatment

- PMLiVE

FDA hands BMS and bluebird bio a priority review for ide-cel

Updated review accepted after refuse-to-file letter was issued in May

- PMLiVE

Janssen scores another expansion for new Darzalex combination in the US

Myeloma med approved in combination with Amgen's Kyprolis

If our patients are diverse, why are clinical trials so white?

Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue...

Blue Latitude Health

- PMLiVE

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

Combination regimen didn't improve progression-free survival

Sanofi reception

FDA approves Sanofi’s key cancer drug Sarclisa for myeloma

First cancer drug wholly owned by company to be approved in past decade

- PMLiVE

Janssen files new Darzalex combination for multiple myeloma

Expands use of anti-CD38 antibody even further

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links